HMGB2/3 was highly expressed in four kinds of cancers, including adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and uterine carcinosarcoma (UCS), while they were down-expressed in acute myeloid leukemia (LAML). Here, HMGB2 is linked to uterine carcinosarcoma.